0000000001117574

AUTHOR

S. Yoshioka

showing 17 related works from this author

Surgeons' fear of getting infected by COVID19: A global survey

2020

During the last three months, COVID- 19 pandemic had led to a serious backlog of operations globally, and plans for restarting operation are imperative. Recommendations for surgical activities were studied, aiming to protect the surgical staff from being infected. In the meantime, it is also important to give attention to the surgeon’s personal feeling during work. We conducted a survey to investigate global surgi- cal practices during the COVID-19 pandemic, and the surgeon’s personal feeling was also investigated in the sur- vey. In this special letter, we performed multivariate analysis to explore factors that associated with surgeon’s fear of getting infected by COVID-19.

Surgery COVID-19medicine.medical_specialty2019-20 coronavirus outbreakInfectious Disease Transmission Patient-to-Professionalsurvey covid19Coronavirus disease 2019 (COVID-19)Attitude of Health PersonnelSettore MED/18 - CHIRURGIA GENERALESevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Infectious Disease TransmissionCOVID-19. Global surgery.MEDLINEGlobal HealthNOPatient-to-ProfessionalTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]Surveys and QuestionnairesCorrespondencemedicineGlobal healthInfection controlHumansGeneralPersonal protective equipmentPersonal Protective EquipmentLS7_4SurgeonsInfection Controlcovid-19; pandemic; surgerySARS-CoV-2business.industrypandemicVaccinationCOVID-19covidFearSettore MED/18Occupational DiseasesCOVID-19; Global Health; Humans; Infection Control; Occupational Diseases; Personal Protective Equipment; Surgeons; Surveys and Questionnaires; Attitude of Health Personnel; Fear; Infectious Disease Transmission Patient-to-ProfessionalSurgeon - infection - COVID19 - surveyFamily medicineSurgerybusiness
researchProduct

Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic

2020

The rapid spread of COVID-19 has changed the global surgical care. Patients infected with COVID-19 may present without typical symptoms, and such asymptomatic patients may potentially trigger in-hospital outbreaks by transmitting the disease to health care providers and other hospitalized patients. Further, asymptomatic COVID-19 patients have worse postop- erative outcomes with an unexpectedly high morbidity and mortality, reaching 20⋅5 per cent deaths. However, we do not have objective global data on this issue. In an attempt to clarify the current global surgical practice under the COVID-19 pandemic particularly focusing on the preoperative screening of asymptomatic COVID-19 patients, we …

2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)covid-19 pandemic surgerySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Settore MED/18 - CHIRURGIA GENERALEMEDLINECOVID-19. Global surgery.AsymptomaticCOVID-19 Critical Pathways Cross Infection Cross-Sectional Studies Health Care Surveys Humans Pandemics Postoperative Complications SARS-CoV-2 Surgical Procedures Operative Asymptomatic InfectionsCOVID-19; Critical Pathways; Cross Infection; Cross-Sectional Studies; Health Care Surveys; Humans; Pandemics; Postoperative Complications; SARS-CoV-2; Surgical Procedures Operative; Asymptomatic InfectionsNOsurgeryTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]Postoperative ComplicationsPandemicCorrespondencemedicineHumansPandemicsAsymptomatic InfectionsLS7_4COVIDCross InfectionSurgical ProceduresCritical pathwaysbusiness.industrySARS-CoV-2pandemicCOVID-19Surgical proceduresOperativeSettore MED/18covid 19 surgical practiceCOVID-19 - surgeryCross-Sectional StudiesSurgical Procedures OperativeHealth Care SurveysEmergency medicineCritical Pathwaysmedicine.symptombusiness
researchProduct

CCDC 910393: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinatescatena-[bis(mu~3~-246-tris(Pyridin-4-yl)-135-triazine)-hexakis(iodo)-tri-zinc(ii) 5678-tetramethoxy-2-(4-methoxyphenyl)-4H-chromen-4-one clathrate unknown solvate]
researchProduct

CCDC 910386: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographyCrystal Systemcatena-[bis(mu~3~-246-tris(Pyridin-4-yl)-135-triazine)-hexakis(iodo)-tri-zinc(ii) hemikis(3-phenylacrylaldehyde) clathrate unknown solvate]Crystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 910380: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographyCrystal SystemCrystal Structurecatena-[octakis(mu~3~-246-tris(Pyridin-4-yl)-135-triazine)-dodecakis(isothiocyanato)-hexa-cobalt(ii) tetrakis(cyclohexanone) clathrate unknown solvate]Cell ParametersExperimental 3D Coordinates
researchProduct

CCDC 910388: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographyCrystal Systemcatena-[bis(mu~3~-246-tris(Pyridin-4-yl)-135-triazine)-hexakis(iodo)-tri-zinc(ii) 9-bromophenanthrene clathrate unknown solvate]Crystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 910391: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

catena-[bis(mu~3~-246-tris(Pyridin-4-yl)-135-triazine)-hexakis(iodo)-tri-zinc(ii) hemikis(2-(34-dimethoxyphenyl)-5678-tetramethoxy-4H-chromen-4-one) clathrate unknown solvate]Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 910389: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameterscatena-[tetrakis(mu~3~-246-tris(Pyridin-4-yl)-135-triazine)-dodecakis(iodo)-hexa-zinc(ii) (dimethyl cubane-14-dicarboxylate) clathrate unknown solvate]Experimental 3D Coordinates
researchProduct

CCDC 910381: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographyCrystal Systemcatena-[bis(mu~3~-246-tris(Pyridin-4-yl)-135-triazine)-hexakis(iodo)-tri-zinc(ii) isoprene clathrate unknown solvate]Crystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 910385: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameterscatena-[bis(mu3-246-tris(Pyridin-4-yl)-135-triazine)-hexakis(iodo)-tri-zinc(ii) 26-di-isopropylaniline clathrate unknown solvate]Experimental 3D Coordinates
researchProduct

CCDC 910387: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographyCrystal SystemCrystal Structurecatena-[tetrakis(mu3-246-tris(Pyridin-4-yl)-135-triazine)-dodecakis(iodo)-hexa-zinc(ii) bis(4-hydroxy-3-methoxybenzaldehyde) clathrate unknown solvate]Cell ParametersExperimental 3D Coordinates
researchProduct

CCDC 910392: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

catena-[bis(mu~3~-246-tris(Pyridin-4-yl)-135-triazine)-hexakis(iodo)-tri-zinc(ii) 2-(34-dimethoxyphenyl)-35678-pentamethoxy-4H-chromen-4-one clathrate unknown solvate]Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 910394: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographycatena-[tetrakis(mu3-246-tris(4-pyridyl)triazine)-dodeca-iodo-hexa-zinc hemikis(miyakosyne A) clathrate]Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 910382: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographycatena-[bis(mu3-246-tris(Pyridin-4-yl)-135-triazine)-hexakis(iodo)-tri-zinc(ii) 7-isopropyl-14-dimethylazulene clathrate unknown solvate]Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 910390: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameterscatena-[octakis(mu3-246-tris(Pyridin-4-yl)-135-triazine)-tetracosakis(iodo)-dodeca-zinc(ii) pentakis(35a9-trimethyl-3a55a9b-tetrahydronaphtho[12-b]furan-28(3H4H)-dione) clathrate cyclohexane unknown solvate]Experimental 3D Coordinates
researchProduct

CCDC 910384: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographycatena-[bis(mu~3~-246-tris(Pyridin-4-yl)-135-triazine)-hexakis(iodo)-tri-zinc(ii) 4-nitrobenzaldehyde clathrate unknown solvate]Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 910383: Experimental Crystal Structure Determination

2013

Related Article: Y.Inokuma,S.Yoshioka,J.Ariyoshi,T.Arai,Y.Hitora,K.Takada,S.Matsunaga,K.Rissanen,M.Fujita|2013|Nature (London)|495|461|doi:10.1038/nature11990

Space GroupCrystallographycatena-[bis(bis(mu~3~-246-tris(Pyridin-4-yl)-135-triazine)-hexakis(iodo)-tri-zinc(ii)) 7-isopropyl-14-dimethylazulene clathrate unknown solvate]Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct